Date:
Novo Nordisk A/S expects sales to surge again this year as the Danish drugmaker builds supply for blockbuster diabetes medicine Ozempic and obesity treatment Wegovy.
Revenue will likely grow by 16% to 24% at constant exchange rates, the company said Wednesday. That compares with 26% for last year. The shares climbed as much as 6.3% in Copenhagen trading after the forecast and better-than-expected results.
NewsGala, a modern financial media outlet by Zeni Capital Corp. With 35 years of international finance expertise NewsGala strips away the distractions to provide timely and relevant financial news.
Our mission is to position our readers to have the best information to make profitable financial decisions and set realistic goals.
© 2021 Newsgala.com. All Rights Reserved.
